Research Analysts Set Expectations for Amarin Q3 Earnings

Amarin Corporation PLC (NASDAQ:AMRN) – Zacks Research dropped their Q3 2026 earnings per share estimates for Amarin in a research report issued to clients and investors on Tuesday, June 16th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of ($0.35) per share for the quarter, down from their previous estimate of ($0.32). Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Amarin’s current full-year earnings is ($1.15) per share. Zacks Research also issued estimates for Amarin’s Q4 2026 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.21) EPS, Q3 2027 earnings at ($0.25) EPS, Q4 2027 earnings at ($0.26) EPS, FY2027 earnings at ($0.88) EPS, Q1 2028 earnings at ($0.15) EPS and FY2028 earnings at ($0.70) EPS.

AMRN has been the topic of a number of other reports. Wall Street Zen downgraded shares of Amarin from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amarin in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Amarin currently has a consensus rating of “Hold” and an average price target of $12.00.

Amarin Price Performance

Shares of Amarin stock opened at $15.77 on Thursday. The firm has a market cap of $330.70 million, a PE ratio of -24.26 and a beta of 0.82. Amarin has a 1 year low of $12.30 and a 1 year high of $20.90. The stock has a fifty day moving average price of $14.60 and a 200-day moving average price of $14.74.

Institutional Trading of Amarin

Hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new position in shares of Amarin during the 1st quarter worth $278,000. Waterfront Wealth Inc. raised its stake in Amarin by 42.7% in the 1st quarter. Waterfront Wealth Inc. now owns 203,338 shares of the biopharmaceutical company’s stock valued at $2,940,000 after acquiring an additional 60,798 shares during the period. XTX Topco Ltd purchased a new stake in Amarin during the fourth quarter valued at about $239,000. Millennium Management LLC boosted its position in Amarin by 25.6% during the fourth quarter. Millennium Management LLC now owns 166,235 shares of the biopharmaceutical company’s stock worth $2,320,000 after purchasing an additional 33,844 shares during the period. Finally, Eversept Partners LP boosted its position in Amarin by 2.9% during the fourth quarter. Eversept Partners LP now owns 172,188 shares of the biopharmaceutical company’s stock worth $2,403,000 after purchasing an additional 4,912 shares during the period. 22.25% of the stock is currently owned by institutional investors.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.